IE35396L - Producing bruncella vaccines. - Google Patents

Abstract

1352125 Antigenic extracts WELLCOME FOUNDATION Ltd 30 June 1971 [16 July 1970] 34457/70 Heading A5B A proteinaceous non-agglutinogenic material, immunogenic in respect of infections of virulent Brucella spp., and free from lipopolysaccharides and formyl groups, is produced by extracting the live bacterial cells of a non- agglutinating strain of a species of the genus Brucella, e.g. Brucella abortus, such as a rough variant of Brucella abortus strain 45/20, in aqueous suspension with a surfactant agent, adding a water-miscible organic solvent to precipitate the extract, e.g. an alkanol having 1 to 3 carbon atoms, acetone, dioxane, and members of the Cellosolve (Trade Mark) and Carbitol (Trade Mark) families, and separating the proteinaceous precipitate from the other materials in the suspension preferably by centrifugation. The surfactant is preferably an anionic surfactant such as an alkali metal (e.g. sodium) salt of dodecyl sulphate. The live cells may be treated with an anionic surfactant at room temperature for 17 to 24 hours. Sterile injectable vaccine preparations comprise the proteinaceous, non-agglutinogenic material and a pharmaceutically acceptable solid or liquid carrier and optionally an aluminium or potash alum adjuvant. The preparation may be freezedried. [GB1352125A]